CAR T-cell therapy bolstered by stiffening up cancer cells first
SkimNews Take
Treating cancer cells to alter their physical properties rather than directly targeting biochemical pathways offers a new avenue for improving immunotherapy efficacy.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Methyl β‑cyclodextrin depletes membrane cholesterol, stiffening cancer cells.
- Li Tang reported that mice receiving CAR T‑cell therapy, IL‑15, and meβCD had a higher survival rate, with five tumors disappearing, while all control mice died.
- CAR T‑cell therapy combined with IL‑15 and meβCD reduced tumor mortality in the melanoma mouse model.
- Yi Sui of Queen Mary University of London called the stiffness‑targeting approach “highly promising.”
- Lance Kam of Columbia University described the results as “quite impressive.”
Why it matters: Patients on CAR T‑cell therapy gain a new approach to improve outcomes; drug developers acquire a combinatorial target, and mortality fell from 100% to 58% in the mouse study.
Ask SkimNews
